Glomeratose A is primarily used in pharmaceutical research due to its unique bioactive properties. It exhibits strong antifungal and antimicrobial activity, making it a candidate for development in topical and systemic treatments against resistant fungal strains. Studies suggest it interferes with cell wall synthesis in pathogenic fungi, which enhances its potential as a lead compound in antifungal drug design. In addition, Glomeratose A has shown immunomodulatory effects in preclinical models, supporting its investigation in inflammatory and autoimmune conditions. Its ability to regulate specific cytokine pathways may offer therapeutic benefits in diseases involving chronic inflammation. Due to its natural origin and structural complexity, it is also used as a reference standard in metabolomic studies of fungal extracts and medicinal plants. Its presence often indicates biosynthetic pathways of interest in biotechnology and drug discovery.